Summary of the CHOICE2 Trial & Related Information:
This text details the results of the CHOICE2 trial,a Phase 3 study investigating the benefit of adding alteplase (a clot-busting drug) directly into the affected brain artery after successful mechanical thrombectomy (physical clot removal) for ischemic stroke.Here’s a breakdown of the key information:
Key Findings:
* Improved Recovery: Patients who received alteplase in addition to thrombectomy showed improved functional recovery at 90 days, with a higher proportion achieving little to no disability. They also demonstrated better independence in daily living and reported improved quality of life.
* Confirmation of Earlier Findings: The results build upon preliminary findings from an earlier, smaller study (CHOICE, published in 2022) which also showed positive outcomes with the combined treatment.
* Safety: The treatment appeared safe, with no meaningful increase in bleeding or mortality.
study Details:
* Participants: 433 adults (median age 76, predominantly white) with ischemic stroke in a large brain artery, treated in Spain between December 2023 and August 2025.
* Procedure: All participants underwent successful mechanical thrombectomy and received alteplase within 24 hours of symptom onset. They were then randomized to receive either usual care or usual care plus an alteplase infusion directly into the affected artery.
* Measurement: Recovery was assessed at 90 days using the modified Rankin Scale (disability), activities of daily living, and a quality of life questionnaire. Safety was monitored through bleeding and mortality rates.
Context & Future Directions:
* Comparable to Other Treatments: Tenecteplase and alteplase (used in the PEARL trial) have shown comparable results.
* Not Instantly Practice-Changing: Experts emphasize that these results are promising but require confirmation in further studies and guideline review before widespread adoption.
* Targeted Treatment: The treatment is highly likely most beneficial for patients who,despite successful clot removal,still have poor blood flow in the smaller blood vessels (microcirculation).
* Future Research: Future studies will focus on understanding and treating the underlying causes of microcirculation disruption.
* Generalizability: While conducted in Spain, the study included participants from 20 countries across three continents, suggesting the results may be applicable to diverse populations.
Limitations:
* Non-Contrast CT scans: The study relied on non-contrast CT scans for follow-up, which may not provide detailed information about brain tissue injury and recovery.
In essence, the CHOICE2 trial provides strong evidence that adding alteplase after successful thrombectomy can improve outcomes for stroke patients, but further research is needed to refine patient selection and establish it as a standard treatment.